Oncotype DX Breast DCIS Score: Essential Genomic Information for Improving Your Treatment Decision
What: The Oncotype DX Breast DCIS Score test is the only genomic test available that helps women recently diagnosed with DCIS, or ductal carcinoma in situ. The test generates a score of 0-100 based on 21 specific genes in your breast tumor tissue that was removed during surgery. This unique set of genes predicts your response to chemotherapy as well as the chances of your cancer returning to provide personalized information that is not available from any other test or measure.
Benefit: For DCIS (Stage 0), the Oncotype DX test can help to predict whether your cancer may come back in the same breast (local recurrence) – a key factor in deciding your treatment following DCIS surgery. Along with the information in your pathology report and other factors, your Oncotype DX test results can help you and your doctor determine the most appropriate treatment options for you based on the biology of your individual cancer.
How: The Oncotype DX test is performed on the tumor tissue sample previously obtained during your original surgery. You will not have to go through any additional surgery or procedure to get the Oncotype DX test.
When: It is important that your doctor request the Oncotype DX breast cancer test before you start any treatment, since the test results are intended for use in guiding the selection of your treatment. Most test results are available within 7 to 10 days from the date your tumor sample is received by the Genomic Health laboratory.
NOTE: If you have early-stage, ER-positive invasive breast cancer, you may be eligible for the Oncotype DX Breast Recurrence Score test.